<p>三菱 UFJ 資產管理有限公司在第二季度購買了 Taysha Gene Therapies, Inc.（NASDAQ:TSHA - 免費報告）的新股份，根據其最近向 SEC 提交的文件。這家機構投資者購買了 80,571 股該公司的股票，價值約為 186,000 美元。</p>
<ul>
<li>Neurogene 股票暴跌 44%：這家生物科技公司還有希望嗎？</li>
</ul>
<p>其他機構投資者和對沖基金最近也調整了對該公司的持股。Y Intercept Hong Kong Ltd 在第一季度購買了 Taysha Gene Therapies 的股份，價值約為 117,000 美元。XTX Topco Ltd 在第一季度購買了 Taysha Gene Therapies 的新頭寸，價值約為 282,000 美元。Jefferies Financial Group Inc.在第一季度收購了 Taysha Gene Therapies 的新股份，價值約為 341,000 美元。BIT Capital GmbH 在第一季度購買了 Taysha Gene Therapies 的股份，價值約為 163,000 美元。最後，Charles Schwab Investment Management Inc.在第一季度將其在 Taysha Gene Therapies 的股份增加了 15.4%。Charles Schwab Investment Management Inc.現在擁有 547,128 股該公司的股票，價值 761,000 美元，此前在該期間又購買了 72,871 股。對沖基金和其他機構投資者持有該公司 77.70% 的股票。</p>
<p>獲取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
<h2>分析師評級變動</h2>
<p>TSHA 最近成為多份分析師報告的主題。Needham &amp; Company LLC 在 10 月 17 日的研究報告中重申了對 Taysha Gene Therapies 的 “買入” 評級，並給出了 10.00 美元的目標價。JMP Securities 在 11 月 5 日的研究報告中設定了 Taysha Gene Therapies 的 8.00 美元價格目標。Cantor Fitzgerald 在週五的研究報告中重新發布了 “增持” 評級，並給出了 13.00 美元的目標價。花旗集團在 11 月 5 日的研究報告中重申了對 Taysha Gene Therapies 的 “跑贏大盤” 評級。最後，Raymond James Financial 在 10 月 21 日的研究報告中開始覆蓋 Taysha Gene Therapies。他們給出了 “強烈買入” 評級和 13.00 美元的目標價。一位研究分析師對該股票給予了強烈買入評級，十位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均價格目標為 10.30 美元。</p>
<ul>
<li>三隻適合您秋季購物清單的小型股</li>
</ul>
<p><strong>閲讀我們關於 TSHA 的最新報告</strong></p>
<h2>內部活動</h2>
<p>在其他新聞中，內部人士 Sukumar Nagendran 在 9 月 10 日的交易中出售了 200,000 股該公司的股票。這些股票以每股平均 3.23 美元的價格出售，總交易額為 646,000.00 美元。交易完成後，該內部人士在公司中持有 1,006,439 股，價值約為 3,250,797.97 美元。這代表了他們持股比例的 16.58% 的下降。該交易已在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。公司內部人士持有該公司 3.78% 的股票。</p>
<h2>Taysha Gene Therapies 股票上漲 3.0%</h2>
<p>Taysha Gene Therapies 的股票在週五開盤時為 4.13 美元。該股票的市值為 11.3 億美元，市盈率為-12.52，貝塔值為 1.00。Taysha Gene Therapies, Inc.的 12 個月低點為 1.05 美元，12 個月高點為 5.51 美元。該公司的流動比率為 10.48，速動比率為 10.48，債務股本比率為 0.23。該公司的 50 日簡單移動平均為 4.10 美元，200 日簡單移動平均為 3.15 美元。</p>
<p>Taysha Gene Therapies（NASDAQ:TSHA - 獲取免費報告）最近在 11 月 4 日發佈了季度收益數據。該公司報告的每股收益為（0.09）美元，符合分析師的共識預期（0.09）。Taysha Gene Therapies 的股本回報率為-67.26%，淨利潤率為-1,144.97%。股票研究分析師預測，Taysha Gene Therapies, Inc.將在本年度發佈-0.35 的每股收益。</p>
<h2>Taysha Gene Therapies 公司簡介</h2>
<p>（免費報告）</p>
<p>Taysha Gene Therapies, Inc.是一家基因治療公司，專注於開發和商業化基於腺病毒相關病毒的基因治療，用於治療中樞神經系統的單基因疾病。它主要開發 TSHA-120 用於治療巨軸神經病；TSHA-102 用於治療 Rett 綜合症；TSHA-121 用於治療 CLN7 疾病；TSHA-118 用於治療 CLN1 疾病；TSHA-105 用於治療 SLC13A5 缺乏症；TSHA-113 用於治療 tau 病；TSHA-106 用於治療 Angelman 綜合症；TSHA-114 用於治療脆性 X 綜合症；以及 TSHA-101 用於治療 GM2 神經節苷脂症。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更喜歡的五隻股票比 Taysha Gene Therapies 更好</li>
<li>市值計算器：如何計算市值</li>
<li>Meta 的痛苦可能是您的收益：這是一個罕見的買入窗口嗎？</li>
<li>低市盈率增長股：解鎖投資機會</li>
<li>三隻被低估的 AI 股票值得在下跌時購買</li>
<li>三隻超市股票證明它們仍然是必需品</li>
<li>您的感恩節投資計劃：三隻受益於足球熱潮的股票</li>
</ul>
<p><strong>想看看其他對沖基金持有 TSHA 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 Taysha Gene Therapies, Inc.（NASDAQ:TSHA - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 Taysha Gene Therapies 嗎？</h2>
<p>在考慮 Taysha Gene Therapies 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Taysha Gene Therapies 並不在名單上。</p>
<p>雖然 Taysha Gene Therapies 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TSHA

<p>三菱 UFJ 資產管理有限公司在第二季度收購了 80,571 股 Taysha Gene Therapies, Inc.，價值約為 186,000 美元。這筆交易是機構投資者調整其在該公司的持股的更廣泛趨勢的一部分。Taysha Gene Therapies 專注於開發針對中樞神經系統疾病的基因療法。分析師對該公司的股票評級為 “適度買入”，目標價格為 10.30 美元</p>

<p>Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 80,571 shares of the company's stock, valued at approximately $186,000.</p>
<div class="lb-trans"><p>三菱 UFJ 資產管理有限公司在第二季度購買了 Taysha Gene Therapies, Inc.（NASDAQ:TSHA - 免費報告）的新股份，根據其最近向 SEC 提交的文件。這家機構投資者購買了 80,571 股該公司的股票，價值約為 186,000 美元。</p>
</div><ul>
<li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li>
</ul>
<div class="lb-trans"><ul>
<li>Neurogene 股票暴跌 44%：這家生物科技公司還有希望嗎？</li>
</ul>
</div><p>Other institutional investors and hedge funds also recently modified their holdings of the company. Y Intercept Hong Kong Ltd purchased a new stake in shares of Taysha Gene Therapies during the 1st quarter valued at about $117,000. XTX Topco Ltd purchased a new position in Taysha Gene Therapies in the 1st quarter worth approximately $282,000. Jefferies Financial Group Inc. acquired a new stake in Taysha Gene Therapies in the first quarter valued at approximately $341,000. BIT Capital GmbH purchased a new stake in shares of Taysha Gene Therapies during the first quarter valued at approximately $163,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Taysha Gene Therapies by 15.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 547,128 shares of the company's stock worth $761,000 after buying an additional 72,871 shares during the period. Hedge funds and other institutional investors own 77.70% of the company's stock.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金最近也調整了對該公司的持股。Y Intercept Hong Kong Ltd 在第一季度購買了 Taysha Gene Therapies 的股份，價值約為 117,000 美元。XTX Topco Ltd 在第一季度購買了 Taysha Gene Therapies 的新頭寸，價值約為 282,000 美元。Jefferies Financial Group Inc.在第一季度收購了 Taysha Gene Therapies 的新股份，價值約為 341,000 美元。BIT Capital GmbH 在第一季度購買了 Taysha Gene Therapies 的股份，價值約為 163,000 美元。最後，Charles Schwab Investment Management Inc.在第一季度將其在 Taysha Gene Therapies 的股份增加了 15.4%。Charles Schwab Investment Management Inc.現在擁有 547,128 股該公司的股票，價值 761,000 美元，此前在該期間又購買了 72,871 股。對沖基金和其他機構投資者持有該公司 77.70% 的股票。</p>
</div><p>Get <strong>Taysha Gene Therapies</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>TSHA has been the topic of a number of recent analyst reports. Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $10.00 target price on shares of Taysha Gene Therapies in a research report on Friday, October 17th. JMP Securities set a $8.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Cantor Fitzgerald reissued an &#34;overweight&#34; rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a research report on Friday. Citigroup reiterated an &#34;outperform&#34; rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Finally, Raymond James Financial assumed coverage on Taysha Gene Therapies in a research report on Tuesday, October 21st. They issued a &#34;strong-buy&#34; rating and a $13.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $10.30.</p>
<div class="lb-trans"><p>TSHA 最近成為多份分析師報告的主題。Needham &amp; Company LLC 在 10 月 17 日的研究報告中重申了對 Taysha Gene Therapies 的 “買入” 評級，並給出了 10.00 美元的目標價。JMP Securities 在 11 月 5 日的研究報告中設定了 Taysha Gene Therapies 的 8.00 美元價格目標。Cantor Fitzgerald 在週五的研究報告中重新發布了 “增持” 評級，並給出了 13.00 美元的目標價。花旗集團在 11 月 5 日的研究報告中重申了對 Taysha Gene Therapies 的 “跑贏大盤” 評級。最後，Raymond James Financial 在 10 月 21 日的研究報告中開始覆蓋 Taysha Gene Therapies。他們給出了 “強烈買入” 評級和 13.00 美元的目標價。一位研究分析師對該股票給予了強烈買入評級，十位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均價格目標為 10.30 美元。</p>
</div><ul>
<li>3 Small-Cap Stocks For Your Fall Shopping List</li>
</ul>
<div class="lb-trans"><ul>
<li>三隻適合您秋季購物清單的小型股</li>
</ul>
</div><p><strong>Read Our Latest Report on TSHA</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 TSHA 的最新報告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other news, insider Sukumar Nagendran sold 200,000 shares of the company's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total transaction of $646,000.00. Following the completion of the transaction, the insider owned 1,006,439 shares in the company, valued at approximately $3,250,797.97. This represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Company insiders own 3.78% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Sukumar Nagendran 在 9 月 10 日的交易中出售了 200,000 股該公司的股票。這些股票以每股平均 3.23 美元的價格出售，總交易額為 646,000.00 美元。交易完成後，該內部人士在公司中持有 1,006,439 股，價值約為 3,250,797.97 美元。這代表了他們持股比例的 16.58% 的下降。該交易已在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。公司內部人士持有該公司 3.78% 的股票。</p>
</div><h2>Taysha Gene Therapies Stock Up 3.0%</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 股票上漲 3.0%</h2>
</div><p>Shares of Taysha Gene Therapies stock opened at $4.13 on Friday. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -12.52 and a beta of 1.00. Taysha Gene Therapies, Inc. has a twelve month low of $1.05 and a twelve month high of $5.51. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. The business's 50 day simple moving average is $4.10 and its 200-day simple moving average is $3.15.</p>
<div class="lb-trans"><p>Taysha Gene Therapies 的股票在週五開盤時為 4.13 美元。該股票的市值為 11.3 億美元，市盈率為-12.52，貝塔值為 1.00。Taysha Gene Therapies, Inc.的 12 個月低點為 1.05 美元，12 個月高點為 5.51 美元。該公司的流動比率為 10.48，速動比率為 10.48，債務股本比率為 0.23。該公司的 50 日簡單移動平均為 4.10 美元，200 日簡單移動平均為 3.15 美元。</p>
</div><p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting analysts' consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（NASDAQ:TSHA - 獲取免費報告）最近在 11 月 4 日發佈了季度收益數據。該公司報告的每股收益為（0.09）美元，符合分析師的共識預期（0.09）。Taysha Gene Therapies 的股本回報率為-67.26%，淨利潤率為-1,144.97%。股票研究分析師預測，Taysha Gene Therapies, Inc.將在本年度發佈-0.35 的每股收益。</p>
</div><h2>Taysha Gene Therapies Company Profile</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.</p>
<div class="lb-trans"><p>Taysha Gene Therapies, Inc.是一家基因治療公司，專注於開發和商業化基於腺病毒相關病毒的基因治療，用於治療中樞神經系統的單基因疾病。它主要開發 TSHA-120 用於治療巨軸神經病；TSHA-102 用於治療 Rett 綜合症；TSHA-121 用於治療 CLN7 疾病；TSHA-118 用於治療 CLN1 疾病；TSHA-105 用於治療 SLC13A5 缺乏症；TSHA-113 用於治療 tau 病；TSHA-106 用於治療 Angelman 綜合症；TSHA-114 用於治療脆性 X 綜合症；以及 TSHA-101 用於治療 GM2 神經節苷脂症。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Taysha Gene Therapies</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>3 Under-the-Radar AI Stocks to Buy on the Dip</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>Your Thanksgiving Playbook: 3 Stocks Set to Benefit From Football Fever</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票比 Taysha Gene Therapies 更好</li>
<li>市值計算器：如何計算市值</li>
<li>Meta 的痛苦可能是您的收益：這是一個罕見的買入窗口嗎？</li>
<li>低市盈率增長股：解鎖投資機會</li>
<li>三隻被低估的 AI 股票值得在下跌時購買</li>
<li>三隻超市股票證明它們仍然是必需品</li>
<li>您的感恩節投資計劃：三隻受益於足球熱潮的股票</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TSHA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有 TSHA 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 Taysha Gene Therapies, Inc.（NASDAQ:TSHA - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TSHA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Taysha Gene Therapies Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Taysha Gene Therapies 嗎？</h2>
</div><p>Before you consider Taysha Gene Therapies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Taysha Gene Therapies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Taysha Gene Therapies 並不在名單上。</p>
</div><p>While Taysha Gene Therapies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Taysha Gene Therapies 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

三菱 UFJ 資產管理有限公司購買了 Taysha Gene Therapies, Inc.的新股份 $TSHA